Henan Lingrui Pharmaceutical Co., Ltd. (SHA: 600285)

Henan Lingrui Pharmaceutical Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Jun 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	726.9	1,499	1,179	801.24	732.32	741.21
Short-Term Investments	130.09	95.63	125.34	140.77	40.08	-
Trading Asset Securities	50.73	0.21	150.42	280.19	57.23	27.83
Cash & Short-Term Investments	907.71	1,595	1,455	1,222	829.63	769.04
Cash Growth	-36.36%	9.60%	19.05%	47.32%	7.88%	18.53%
Accounts Receivable	706.1	498.99	511.97	431.18	708.6	644.27
Other Receivables	15.18	19.35	21.37	9.58	8.54	18.69
Receivables	721.28	518.34	533.34	440.77	717.13	662.95
Inventory	439.16	467.35	486.41	428.39	331.41	286.68
Prepaid Expenses	-	-	-	-	0.38	0.38
Other Current Assets	31.4	18.51	33.58	39.87	37.98	35.31
Total Current Assets	2,100	2,599	2,508	2,131	1,917	1,754
Property, Plant & Equipment	621.48	647.81	706.76	732.92	730.03	766.04
Long-Term Investments	1,519	1,069	676.63	364.7	349.75	333.89
Goodwill	-	-	-	-	-	0.5
Other Intangible Assets	204.3	202.5	203.65	236.95	235.04	242.05
Long-Term Deferred Tax Assets	206.57	186.92	159.2	116.49	97.79	78.41
Long-Term Deferred Charges	30.14	36.73	51.54	65.53	87.15	98.05
Other Long-Term Assets	33.05	29.98	38.45	145.25	41.45	42.48
Total Assets	4,714	4,772	4,345	3,793	3,458	3,316
Accounts Payable	91.17	57.38	68.02	78.01	78.81	67.66
Accrued Expenses	1,245	1,110	917.79	600.38	528.26	415.85
Short-Term Debt	76.03	199.94	151.15	272.34	166	281
Current Portion of Leases	1.21	1.08	1.22	1.65	-	-
Current Income Taxes Payable	75.61	70.72	55.54	46.9	52.46	47.18
Current Unearned Revenue	90.8	114.48	153.75	79.09	71.73	-
Other Current Liabilities	359.35	346.95	364.47	359.28	169.01	202.1
Total Current Liabilities	1,939	1,900	1,712	1,438	1,066	1,014
Long-Term Leases	6.77	6.96	6.2	7.9	-	-
Long-Term Unearned Revenue	36.77	39.78	38.55	42.78	48.26	55.04
Long-Term Deferred Tax Liabilities	20.39	26.32	29.56	18.18	21.09	26.5
Total Liabilities	2,003	1,973	1,786	1,507	1,136	1,095
Common Stock	567.14	567.14	567.46	567.76	567.81	567.81
Additional Paid-In Capital	330.33	326.23	309.82	272.02	319.63	326.08
Retained Earnings	1,856	1,894	1,664	1,481	1,340	1,185
Treasury Stock	-44.23	-47.4	-67.62	-98.19	-	-
Comprensive Income & Other	-5.98	51	76.74	56.08	84.87	130.73
Total Common Equity	2,703	2,791	2,551	2,279	2,313	2,210
Minority Interest	7.77	7.66	7.55	7.59	9.43	10.56
Shareholders' Equity	2,711	2,799	2,558	2,287	2,322	2,220
Total Liabilities & Equity	4,714	4,772	4,345	3,793	3,458	3,316
Total Debt	84.01	207.99	158.57	281.89	166	281
Net Cash (Debt)	823.7	1,387	1,296	940.31	663.63	488.04
Net Cash Growth	-36.29%	6.96%	37.88%	41.69%	35.98%	31.09%
Net Cash Per Share	1.46	2.45	2.28	1.66	1.17	0.85
Filing Date Shares Outstanding	563.19	563.94	569.61	564.55	562.16	567.81
Total Common Shares Outstanding	563.19	563.94	569.61	564.55	567.81	567.81
Working Capital	160.49	698.77	796.44	693.59	850.28	740.57
Book Value Per Share	4.80	4.95	4.48	4.04	4.07	3.89
Tangible Book Value	2,499	2,589	2,347	2,042	2,078	1,967
Tangible Book Value Per Share	4.44	4.59	4.12	3.62	3.66	3.46
Buildings	592.57	593.96	595.01	582.83	577.6	577.01
Machinery	586.93	581.63	581.92	534.7	511.65	492.22
Construction In Progress	2.44	2.88	1.92	24.78	2.78	9.03

Source: S&P Capital IQ. Standard template. Financial Sources.